Ternary Secures Seed Funding to Revolutionize AI-Driven Molecular Glue Discovery

Ternary, a London-based biotech startup, has secured seed funding from daphni, a venture capital firm specialising in early-stage European science companies. The investment comes as daphni closes its Blue fund at €260 million, reinforcing its focus on startups with strong scientific foundations. Ternary aims to revolutionise molecular glue discovery using AI and rapid lab testing to reduce reliance on chance findings.

Founded in October 2024, Ternary operates from London with lab facilities at the Stevenage Bioscience Catalyst. The site has expanded its research capabilities since 2021, particularly in targeted protein degradation and proteomics, though exact investment figures remain undisclosed.

The startup's approach combines physics-informed AI, molecular dynamics, and fast experimental validation in a continuous cycle. This method seeks to make molecular glue discovery more predictable, moving away from traditional trial-and-error processes. While the seed funding amount is modest, it reflects the growing challenge of securing early-stage investment in Europe's competitive techbio sector. Ternary has strengthened its leadership by appointing Ian Taylor, the former president of R&D at Arvinas, to its board. His experience in targeted protein degradation adds weight to the company's ambitions. The firm's preclinical pipeline currently focuses on immunological disorders, with future success hinging on converting its platform technology into viable clinical candidates and partnerships.

The funding from daphni positions Ternary to advance its AI-driven platform for molecular glue discovery. With a preclinical pipeline and a seasoned board, the company now faces the task of turning its scientific approach into tangible results. The outcome will test whether its closed-loop system can deliver partner-ready data and clinical progress in the coming years.